Eisai starts two phase III studies for antiepileptic drug perampanel
Eisai has started two phase III clinical studies for its in-house-discovered antiepileptic drug (AED) perampanel (generic name: perampanel hydrate, product name: Fycompa) as adjunctive therapy in pediatric patients with partial-onset seizures or primary generalized tonic-clonic seizures (Study 311) and in patients with seizures associated with Lennox-Gastaut syndrome (LGS, Study 338).
The study will evaluate the safety, tolerability, and exposure-efficacy relationship of perampanel when administered as an adjunctive therapy.
